跳至主要内容
临床试验/CTRI/2021/10/037538
CTRI/2021/10/037538尚未招募2 期

A PROSPECTIVE STUDY OF CHEMOTHERAPY FOLLOWED BY STEREOTACTIC BODY RADIATION THERAPY(SBRT) IN BORDERLINE RESECTABLE PANCREATIC CANCER(BRPC) AND LOCALLY ADVANCED PANCREATIC CANCER (LAPC)

PGIMER CHANDIGARH0 个研究点目标入组 0 人开始时间: 待定最近更新:

试验速览

阶段
2 期
状态
尚未招募

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional

入排标准

入选标准

  • 1. Histologically confirmed adenocarcinoma of pancreas
  • 2. Determined borderline resectable or locally advanced.
  • 3. Induction modified FOLFIRINOX/ Gemcitabine based combination/ Gemcitabine-nab paclitaxel up to 3cycles.
  • 4. Stable or disease regression on re staging scans.
  • 5. Tumour diameter 7 cm
  • 6. Satisfying the radiation normal tissue constraints as per protocol.
  • 7. ECOG 0,1,2
  • 8. Patients must have acceptable organ and marrow function:
  • 9. Ability to understand and willingness to sign an informed consent.

排除标准

  • 1.Tumor in growth into stomach or duodenum
  • 2.Metastatic disease
  • 3. Patients who have had prior radiotherapy to upper abdomen/liver.
  • 4. Patients who have received prior chemotherapy for pancreatic cancer, other than Gemcitabine/ nab paclitaxel/ FOLFIRINOX
  • 5. Uncontrolled intercurrent illness including but not limited to ongoing iOS active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia,or psychiatric illness/ social situations that would limit compliance with study requirements.

研究者

相似试验